Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17925539 | 1.00 | HDAC1 (0.39) | HDAC1GPR119HSD11B1MAP4K4ELANE | |
| SCHEMBL17936825 | 1.00 | HDAC1 (0.39) | HDAC1GPR119HSD11B1MAP4K4ELANE | |
| SCHEMBL21058315 | 0.87 | GPR119 (0.38) | HDAC1GPR119HSD11B1MAP4K4ELANE | |
| SCHEMBL19632326 | 0.87 | GPR119 (0.38) | HDAC1GPR119HSD11B1MAP4K4ELANE | |
| SCHEMBL21260292 | 0.86 | GPR119 (0.37) | HDAC1GPR119HSD11B1MAP4K4ELANE | |
| SCHEMBL22615358 | 0.85 | MEN1 (0.39) | HDAC1GPR119HSD11B1MAP4K4ELANE | |
| SCHEMBL20691685 | 0.85 | MEN1 (0.39) | HDAC1GPR119HSD11B1MAP4K4ELANE | |
| SCHEMBL19632319 | 0.85 | GPR119 (0.37) | HDAC1GPR119HSD11B1MAP4K4ELANE | |
| SCHEMBL19632470 | 0.85 | GPR119 (0.37) | HDAC1GPR119HSD11B1MAP4K4ELANE | |
| SCHEMBL28357282 | 0.84 | ELANE (0.36) | HDAC1GPR119HSD11B1ELANEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109952305-B | Piperazino heteroaryl derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20220162212-A1 | PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE-5-CARBOXAMIDE | HOFFMANN-LA ROCHE INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220162212-A1 | PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE-5-CARBOXAMIDE | HOFFMANN-LA ROCHE INC. (US) | 2022-05-26 | — | — | US | disclosed |
| CN-109476668-B | 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazines and 6, 7-dihydro-4H-triazolo [1,5-a ] pyrazines for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11247998-B2 | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| CN-113454088-A | Process for the preparation of (6S) -3- [ (4S) -4-cyano-2-oxo-pyrrolidin-1-yl ] -6-methyl-N- (3,4, 5-trifluorophenyl) -6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazine-5-carboxamide | 豪夫迈·罗氏有限公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-3458455-B1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| CN-109153682-B | Novel pyrazine compounds with oxygen, sulfur and nitrogen linkers for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2021-05-25 | — | — | CN | disclosed |
| WO-2018011160-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018011162-A1 | CARBOXY 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018011160-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018011163-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2017198744-A1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-23 | — | — | WO | disclosed |
| EP-3245206-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. Hoffmann-La Roche AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247998-B2 | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | IKZF2, WEE1, NOTUM | HDAC1 274/4885GPR119 3652/4885HSD11B1 540/4885 |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | CYP3A5, HAVCR2, HCCS | HDAC1 614/4885GPR119 1377/4885HSD11B1 578/4885 |
| US-20220162212-A1 | PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE-5-CARBOXAMIDE | HCCS, CYP2S1, CYP3A5 | HDAC1 309/4885GPR119 3960/4885HSD11B1 1029/4885 |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, NR1H4, ZC3HAV1 | HDAC1 443/4885GPR119 269/4885HSD11B1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.